share_log

Rockwell Medical Partners With HydroCare to Distribute and Install Its Dry Acid Concentrate Mix System

Rockwell Medical Partners With HydroCare to Distribute and Install Its Dry Acid Concentrate Mix System

rockwell medical與HydroCare合作,分銷和安裝其幹酸濃縮混合系統。
Rockwell Medical ·  12/05 13:00

WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has partnered with HydroCare, a leading provider of state-of-the-art dialysis water treatment systems to healthcare facilities globally, to purchase and install the Company's dry acid concentrate mix system in dialysis water rooms. Rockwell anticipates that with these new mixer installations through HydroCare, the Company will also generate new sales related to its dry acid hemodialysis concentrates. Rockwell Medical's DAMX45 dry acid concentrate mix system is 510(k) approved to be used exclusively with the Company's CitraPure                                                                                 and Dri-Sate                                                                                 dry acid concentrate powders.                                    

密歇根州 WixOM--(美國商業資訊)--Rockwell Medical, Inc.(「公司」)(納斯達克股票代碼:RMTI)是一家開發、製造、商業化並向全球透析提供商分銷血液透析產品組合的醫療保健公司,今天宣佈,該公司已與向全球醫療機構提供最先進透析水處理系統的領先供應商HydroCare合作,在透析水中購買和安裝公司的幹酸濃縮混合系統房間。羅克韋爾預計,通過HydroCare安裝這些新的攪拌機,該公司還將創造與其幹酸血液透析濃縮液有關的新銷售額。羅克韋爾醫療的 DAMX45 幹酸濃縮物混合系統已獲得 510 (k) 批准,只能與該公司的 CitraPure 和 Dri-Sate 幹酸濃縮粉末一起使用。

"The dialysis water room is the heartbeat of the dialysis unit, housing the systems that provide highly purified water. It requires regular upkeep to stay clean and toxin-free," says Eric Cirignano, Founder and CEO of HydroCare. "At HydroCare, we focus on providing reliable dialysis water treatment systems that put patient safety first. Our product range includes large RO systems, disposables, and replacement parts. We needed a simple, easy-to-train solution for dry acid mixers, and found that and more with Rockwell Medical's 'ready-to-use' DAMX45 dry acid concentrate mix system."

「透析水室是透析裝置的心跳,裏面裝有提供高度純淨水的系統。它需要定期維護才能保持清潔和無毒。」 HydroCare創始人兼首席執行官埃裏克·西里尼亞諾說。「在HydroCare,我們專注於提供可靠的透析水處理系統,將患者安全放在首位。我們的產品範圍包括大型反滲透系統、一次性用品和替換部件。我們需要一種簡單、易於訓練的幹酸混合器解決方案,在羅克韋爾醫療'即用型'的 DAMX45 幹酸濃縮物混合系統中發現了這一點以及更多。」

"We are excited to partner with HydroCare to sell and install our dry acid mixers as part of their dialysis water room installations," said                                         Tim Chole, Chief Commercial Officer at Rockwell Medical. "Our mixer is compact, quick and easy to install, and FDA-approved for Rockwell's dry acid products. Using a forced RO water pump to mix the product, our mixer enables a dialysis clinic to mix 100 gallons of acid concentrate on-site in just three minutes. We believe that this partnership with HydroCare offers us another avenue to install Rockwell's mixers into more clinics to benefit more patients."                                    

羅克韋爾醫療首席商務官蒂姆·喬爾表示:「我們很高興能與HydroCare合作,銷售和安裝我們的幹酸混合器,作爲其透析水室設施的一部分。」「我們的混合器結構緊湊,安裝快捷方便,經美國食品藥品管理局批准,適用於羅克韋爾的幹酸產品。我們的混水器使用強制反滲透水泵來混合產品,使透析診所能夠在短短三分鐘內在現場混合 100 加侖的濃縮酸。我們相信,與HydroCare的合作爲我們提供了另一種途徑,可以將羅克韋爾的混合器安裝到更多診所,使更多患者受益。」

About HydroCare

關於 HydroCare

HydroCare isn't just meeting the dialysis community's stringent water filtration standards—we're revolutionizing them. Our dialysis water system are engineered to guarantee that patients receive nothing less than the safest, most reliable water for their treatments, every single time. By integrating technologies like reverse osmosis, innovative endotoxin-retentive filters, and cutting-edge pretreatment systems, HydroCare obliterates organic and inorganic contaminants. This is how we redefine the future of dialysis water—pure, compliant, and uncompromising in quality. For more information, visit                                         hydrocare.us.                                    

HydroCare 不僅滿足透析界嚴格的濾水標準,我們還在對其進行革新。我們的透析用水系統經過精心設計,可確保患者每次都能獲得最安全、最可靠的治療用水。通過整合反滲透、創新的內毒素保留過濾器和尖端預處理系統等技術,HydroCare 可以去除有機和無機污染物。這就是我們重新定義透析水未來的方式——純淨、合規、質量毫不妥協。欲了解更多信息,請訪問 hydrocare.us。

About Rockwell Medical

關於羅克韋爾醫療

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient's home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work                                                                                 in 2023 and 2024 and named                                         Fortune                                         Best Workplaces in Manufacturing & Production                                        TM                                         in 2024, Rockwell Medical is                                                                                    Driven to Deliver Life-Sustaining Dialysis Solutions                                            TM                                            .                                                                                For more information, visit                                         .                                    

羅克韋爾醫療公司(納斯達克股票代碼:RMTI)是一家醫療保健公司,爲全球透析提供商開發、製造、商業化和分銷血液透析產品組合。Rockwell Medical的使命是爲透析診所及其服務的患者提供業內最佳客戶服務支持的最高質量的產品。羅克韋爾專注於創新的長期增長戰略,以增強其產品、流程和員工,使公司能夠爲醫療保健系統創造非凡的價值,並對血液透析患者的生活產生積極影響。血液透析是最常見的終末期腎臟疾病治療形式,通常在獨立的門診透析中心、醫院門診中心、專業護理機構或患者家中進行。Rockwell Medical的產品對終末期腎臟疾病的弱勢患者至關重要,該公司堅持不懈地提供無與倫比的可靠性和客戶服務。羅克韋爾醫療在2023年和2024年被認證爲最佳工作場所,並於2024年被評爲《財富》製造與生產領域最佳工作場所Tm,致力於提供維持生命的透析解決方案Tm。欲了解更多信息,請訪問。

Forward-Looking Statements

前瞻性陳述

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," "are determined," "are on track," "are resolute in our vision," or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements include statements relating to generating new sales and installing the Rockwell Medical mixer into additional dialysis clinics. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

本新聞稿中的某些陳述可能構成聯邦證券法所指的 「前瞻性陳述」。諸如 「可能」、「可能」、「將」、「應該」、「相信」、「期望」、「預測」、「估計」、「繼續」、「可以」、「會」、「發展」、「計劃」、「潛力」、「預測」、「項目」、「打算」、「期待」、「保持信心」、「保持信心」 等詞語是堅定的,” 「步入正軌」、「堅定不移地實現我們的願景」,或這些條款的否定之處,以及類似的表達,或有關意圖、信念或當前期望的陳述,均爲前瞻性陳述。這些聲明包括與創造新銷售額以及在其他透析診所安裝羅克韋爾醫療混頻器有關的聲明。儘管羅克韋爾醫療認爲這些前瞻性陳述是合理的,但不應過分依賴任何此類前瞻性陳述,這些陳述是基於我們在本新聞稿發佈之日獲得的信息。這些前瞻性陳述基於當前的估計和假設,受各種風險和不確定性的影響(包括但不限於羅克韋爾醫療在美國證券交易委員會文件中列出的風險和不確定性),其中許多風險和不確定性是我們無法控制的,可能會發生變化。實際結果可能存在重大差異。風險和不確定性包括但不限於我們在截至2023年12月31日止年度的10-k表年度報告的 「風險因素」 部分中更全面地討論的風險,因爲此類描述可能會在我們向美國證券交易委員會提交的任何未來報告中進行修改或更新。除非法律要求,否則羅克韋爾醫療明確表示不承擔任何更新我們的前瞻性陳述的義務。

Heather R. Hunter                                        
SVP, Chief Corporate Affairs Officer                                        
(248) 432-1362                                        
IR@RockwellMed.com

希瑟·R·亨特
高級副總裁、首席企業事務官
(248) 432-1362
IR@RockwellMed.com

Source: Rockwell Medical

來源:羅克韋爾醫療

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論